Immunome Stock

Immunome Net Margin

The Net Profit Margin of Immunome (IMNM) as of Aug 16, 2026 is -3,059.99 %. In the previous year, Net Profit Margin was -3,240.38 % — a change of -5.57% (higher).

Net Margin

-3,059.99 %

YoY

-5.57%

Last updated:

Net Profit Margin of Immunome is 2026 -3,059.99 % . Net Profit Margin of Immunome was 2025 -3,240.38 % . It decreases by -5.57% higher compared to the previous year.

For Immunome, the net margin of -3,060.0% is down versus -556.8% a few years ago.

Access this data via the Eulerpool API

Immunome Stock analysis

What does Immunome do? Immunome Inc was founded in 2020 and is based in Pennsylvania, USA. The company specializes in researching and developing therapeutic antibodies and vaccines. Its goal is to develop innovative drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The history of Immunome Inc began with the founding by a group of scientists and entrepreneurs who combined their expertise and experience in the field of immunology and biotechnology. Their goal was to build a company capable of conducting groundbreaking research and developing new therapies that offer improved chances of recovery. The business model is based on the discovery and development of monoclonal antibodies that have high specificity and effectiveness against specific target molecules. The strategy is to focus on new approaches to identify target molecules in order to develop drugs that specifically target the causes of diseases. Immunome Inc specializes in various areas: cancer, infectious diseases, and autoimmune diseases. Within these areas, the company focuses on identifying target molecules and developing monoclonal antibodies and vaccines that act specifically against these molecules. Products offered by Immunome Inc include monoclonal antibodies against various types of cancer such as breast cancer, prostate cancer, and lung cancer. These antibodies are currently being tested in clinical trials and show promising results. The company also offers a range of vaccines against various infectious diseases, including adaptable influenza vaccines and vaccines against the Ebola virus. In addition, Immunome Inc places great importance on the development of therapies for autoimmune diseases. This includes, for example, the discovery of autoantibodies that selectively balance the immune system and thus can control autoimmune diseases. In summary, Immunome Inc is an innovative biotech company specializing in the development and commercialization of monoclonal antibodies and vaccines against cancer, infectious diseases, and autoimmune diseases. Through its groundbreaking research, the company has the potential to save lives and contribute to the cure of diseases. Immunome is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunome stock

Net Profit Margin of Immunome is -3,059.99 % in 2026.

Net Profit Margin of Immunome changed from -3,240.38 % to -3,059.99 %, representing a -5.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Immunome since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Immunome with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Immunome

All Key Metrics — Immunome